| Project/Area Number |
26861241
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Anesthesiology
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
OGAWA SATORU 京都府立医科大学, 医学(系)研究科(研究院), 助教 (50636131)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 直接作用型抗凝固薬 / 血栓 / フローチャンバー / プロトロンビン複合体製剤 / 新鮮凍結血漿 / 新規抗凝固薬 / 血液凝固 / 急性拮抗 / 出血 |
|---|
| Outline of Final Research Achievements |
There are no specific antidotes available for Direct Oral Anticoagulants (DOACs). In this study, we evaluated the effect of DOACs on clot formations and reversal agents under flow conditions.
All antidotes such as fresh-frozen plasma (FFP), recombinant factor VIIa, prothrombin complex concentrates (PCCs) showed reversal effect of static coagulation parameters in dabigatran-, rivaroxaban, or apixaban- treated plasma. Under flow condition using flow condition, PCCs improved clot formation, but FFP did not. Thrombin generation assay showed the insufficient effect of FFP, which is one of the reason caused discrepancy between static and dynamic conditions. PCCs are useful antidotes for DOACs, and Flow chamber assays are possible monitoring devices for evaluating the effect of DOACs and its reversal.
|
